417 related articles for article (PubMed ID: 35714328)
41. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
42. The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants.
Koutsakos M; Lee WS; Reynaldi A; Tan HX; Gare G; Kinsella P; Liew KC; Taiaroa G; Williamson DA; Kent HE; Stadler E; Cromer D; Khoury DS; Wheatley AK; Juno JA; Davenport MP; Kent SJ
Immunity; 2022 Jul; 55(7):1316-1326.e4. PubMed ID: 35690062
[TBL] [Abstract][Full Text] [Related]
43. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant.
He C; Yang J; Hong W; Chen Z; Peng D; Lei H; Alu A; He X; Bi Z; Jiang X; Jia G; Yang Y; Zhou Y; Yu W; Tang C; Huang Q; Yang M; Li B; Li J; Wang J; Que H; Chen L; Ren W; Wan D; Li J; Wang W; Shen G; Zhao Z; Yang L; Yang J; Wang Z; Su Z; Wei Y; Cen X; Tanaka Y; Song X; Lu S; Peng X; Lu G; Wei X
Nat Commun; 2022 Sep; 13(1):5459. PubMed ID: 36115859
[TBL] [Abstract][Full Text] [Related]
44. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.
Chen Z; Zhang Y; Wang M; Islam MS; Liao P; Hu Y; Chen X
Int J Biol Sci; 2022; 18(12):4629-4641. PubMed ID: 35874952
[TBL] [Abstract][Full Text] [Related]
45. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
46. Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.
Seaman MS; Siedner MJ; Boucau J; Lavine CL; Ghantous F; Liew MY; Mathews JI; Singh A; Marino C; Regan J; Uddin R; Choudhary MC; Flynn JP; Chen G; Stuckwisch AM; Lipiner T; Kittilson A; Melberg M; Gilbert RF; Reynolds Z; Iyer SL; Chamberlin GC; Vyas TD; Vyas JM; Goldberg MB; Luban J; Li JZ; Barczak AK; Lemieux JE
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36214224
[TBL] [Abstract][Full Text] [Related]
47. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
Zou Y; Huang D; Jiang Q; Guo Y; Chen C
Front Public Health; 2022; 10():940956. PubMed ID: 35910897
[TBL] [Abstract][Full Text] [Related]
48. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
49. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
[TBL] [Abstract][Full Text] [Related]
50. Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern.
Svetlova J; Gustin D; Manuvera V; Shirokov D; Shokina V; Prusakov K; Aldarov K; Kharlampieva D; Matyushkina D; Bespyatykh J; Varizhuk A; Lazarev V; Vedekhina T
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362010
[TBL] [Abstract][Full Text] [Related]
51. Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination.
Kurahashi Y; Furukawa K; Sutandhio S; Tjan LH; Iwata S; Sano S; Tohma Y; Ohkita H; Nakamura S; Nishimura M; Arii J; Kiriu T; Yamamoto M; Nagano T; Nishimura Y; Mori Y
J Infect Dis; 2022 Oct; 226(8):1391-1395. PubMed ID: 35512332
[TBL] [Abstract][Full Text] [Related]
52. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.
Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ
J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398
[TBL] [Abstract][Full Text] [Related]
53. Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants.
Xie Y; Liu L; Wang J; Zheng Y; Luo C; Ni W; He Z; Zhao X; Liu Y; He Y; Zheng S; Li L; Liu Z
Front Immunol; 2022; 13():975533. PubMed ID: 36248883
[TBL] [Abstract][Full Text] [Related]
54. Humoral and adaptive immune responses to the SARS-CoV-2 vaccine.
Rizzo R; Bortolotti D; Morandi L; Rizzo S; Schiuma G; Beltrami S; Papi A; Contoli M
Int J Infect Dis; 2022 Sep; 122():412-414. PubMed ID: 35750264
[TBL] [Abstract][Full Text] [Related]
55. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
56. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
Front Immunol; 2022; 13():909910. PubMed ID: 35784321
[TBL] [Abstract][Full Text] [Related]
57. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
59. Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.
Storti P; Marchica V; Vescovini R; Franceschi V; Russo L; Notarfranchi L; Raimondi V; Toscani D; Burroughs Garcia J; Costa F; Dalla Palma B; Iannozzi NT; Sammarelli G; Donofrio G; Giuliani N
Oncoimmunology; 2022; 11(1):2120275. PubMed ID: 36105747
[TBL] [Abstract][Full Text] [Related]
60. Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination.
Wang M; Zhou B; Fan Q; Zhou X; Liao X; Lin J; Ma Z; Dong J; Wang H; Ge X; Ju B; Zhang Z
Emerg Microbes Infect; 2023 Dec; 12(1):2151381. PubMed ID: 36444724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
